Tumour expressions of hypoxic markers predict the response to neo-adjuvant chemotherapy in children with inoperable rhabdomyosarcoma

Krawczyk, Małgorzata; Sokolewicz, E; Kunc, Michał; Gabrych, Anna; Fatyga, Aleksandra; Iżycka-Świeszewska, Ewa; Kazanowska, Bernarda; Adamkiewicz-Drożyńska, Elżbieta; Bień, Ewa

doi:10.1080/1354750x.2019.1606275

Cited by 14 publications

(13 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous studies have shown that GLUT-1 overexpression in tumours from different sites can suggest a worse prognosis, such as in colorectal cancer [ 9 ], lung cancer [ 10 ], mesothelioma [ 11 ], head and neck carcinoma [ 12 ], ovarian cancer [ 13 ], urothelial carcinoma [ 14 ], prostate cancer [ 15 ], esophagogastric cancer [ 16 , 17 ] and sarcomas [ 18 ]. The existing data on the prognostic significance of the overexpression of GLUT-1 in pancreatic ductal adenocarcinoma (PDAC) has been limited and not consistent, having increased exponentially in recent years with positive results.…”

Section: Introductionmentioning

confidence: 99%

GLUT-1 as a predictor of worse prognosis in pancreatic adenocarcinoma: immunohistochemistry study showing the correlation between expression and survival

et al. 2020

View full text Add to dashboard Cite

Background Various parameters have been considered for predicting survival in pancreatic ductal adenocarcinoma. Information about western population is missing. The aim of this study is to assess the association between Glucose transporter type 1 (GLUT-1) expression and prognosis for patients with PDAC submitted for surgical resection in a European cohort. Methods Retrospective analysis of PDAC specimens after pancreatoduodenectomy assessing GLUT-1 expression according to intensity (weak vs strong) and extension (low if < 80% cells were stained, high if > 80%) was performed. Statistical analysis was performed using the exact Fisher test, Student t test or the Mann-Whitney U test. Survival was analysed using the Kaplan-Meier method and compared with the Log-rank test. The differences were considered significant at a two-sided p value of < 0.05. All statistical analyses were performed using SPSS® 23.0 for Windows (SPSS Inc., Chicago, IL, USA). Results Our study consisted of 39 patients of which 58.9% presented with weak and 41.1% with strong intensity. The median extension was 90%: 28.2% cases presented with a low extension and 71.8% with a high extension. No significant differences related to intensity were found. The high-extension group showed a higher percentage of T3 PDAC (92.9% vs 63.6%, p = 0.042) and LNR20 (35.7% vs 0%, p = 0.037) as well as shorter disease-free survival (17.58 vs 54.46 months; p = 0.048). Conclusions Our findings suggest that GLUT-1 could be related to higher aggressivity in PDAC and could be used as a prognostic marker, identifying patients with a worse response to current therapies who could benefit from more aggressive treatments.

show abstract

Section: Introductionmentioning

confidence: 99%

GLUT-1 as a predictor of worse prognosis in pancreatic adenocarcinoma: immunohistochemistry study showing the correlation between expression and survival

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A correlation between high VEGF/VEGFR levels and poor outcomes in pediatric solid tumors such as neuroblastoma, Wilms tumor, Ewing sarcoma, osteosarcoma and rhabdomyosarcoma suggested that angiogenesis inhibitors might offer a therapeutic approach. [2][3][4][5][6][7][8][9][10][11][12][13][14] Apatinib, an oral VEGFR-2 TKI, was approved by both the FDA (Food and Drug Administration) and CFDA (China Food and Drug Administration) for the treatment of patients with metastatic gastric cancer. It was also demonstrated to improve progression-free survival (PFS) and overall survival (OS) in patients with breast cancer, 15 non-small cell lung cancer, 16 ovarian cancer, 17,18 hepatocellular carcinoma, 19 bone and soft tissue sarcomas, 20 etc.…”

Section: Introductionmentioning

confidence: 99%

<p>The Efficacy and Safety of Apatinib in Refractory/Relapse Advanced Pediatric Solid Tumor: A Retrospective Study</p>

Sun

Lü

Zhen

et al. 2020

CMAR

View full text Add to dashboard Cite

Background: The prognosis of recurrent or refractory advanced childhood solid tumor patients is very poor and new therapeutic strategies are in urgent need. This study aimed to determine the efficacy and safety of apatinib in pediatric refractory/relapse advanced solid tumor patients. Patients and Methods: The study retrospectively reviewed recurrent or refractory advanced pediatric solid tumor patients who were treated with apatinib, an oral smallmolecule tyrosine kinase inhibitor (TKI) that targets vascular endothelial growth factor receptor-2 (VEGFR2), at the Sun Yat-sen University Cancer Center (China) from January 2016 to March 2019. Results: Fifty-six patients were included in the safety evaluation and 49 patients were included in the efficacy evaluation. The objective responses rate (ORR) was 26.5% (95% CI 15-41): 0 CR (complete response) and 13 PR (partial response). Disease control rate (DCR) (CR+PR+SD) was 79.6% (95% CI 65-90). The median progression-free survival (PFS) was 4.0 months (95% CI 2.6-5.4). There was no significant difference for ORR or PFS between the A (apatinib monotherapy), A+MT (apatinib combined with oral metronomic therapy) and A+SC (apatinib combined with salvage combination chemotherapy) group (p>0.05). The most common grade 3 or 4 adverse events were neutropenia (9[16.1%]), thrombocytopenia (8[14.3%]), hand-foot syndrome (3[5.4%]), hypertension (3[5.4%]), anaemia (3[5.4%]) and mucositis (2[3.6%]). Hypertension was the most serious adverse event and one death that occurred was considered as drug-related. Conclusion: Apatinib showed promising clinical activity in heavily treated recurrent or refractory advanced childhood solid tumor patients. However, it is necessary to pay special attention to monitoring blood pressure when using apatinib in children. Prospective randomized controlled clinical trial is warranted.

show abstract

“…[39] The IHC expression pattern of endogenous markers has emerged as a promising tool to predict the response to neoadjuvant chemotherapy for RMS. [40] A five-gene expression signature score shows a significant correlation with overall and FFS among cases from COG D9803. [41] However, these findings are awaiting further translation or validation in clinical trials.…”

Section: Discussionmentioning

confidence: 95%

Recurrence of low-risk vaginal embryonal rhabdomyosarcoma: A case report and literature review

Peng

You

2020

Preprint

View full text Add to dashboard Cite

Background Low-risk vaginal embryonal rhabdomyosarcoma (ERMS) requires no radiotherapy (RT) for local control. Case summary A 32-month-old girl presented with an exophytic vaginal botryoid mass, which was confirmed of be ERMS. She was given two courses of vincristine, topotecan, and cyclophosphamide (VAC) as neoadjuvant therapy, after which she underwent a hysteroscopy and conservative resection of the vaginal lesion with a negative margin. She was diagnosed with low-risk ERMS (stage I, subgroup A and Group I) and was discharged after another four courses of VAS. However, twenty-eight months after the last treatment, she presented with a giant mass protruding through the vaginal introitus, which was confirmed to be a recurrence of ERMS. Despite multiple rounds of therapy, the patient died 39 months after her diagnosis, at 5 years of age. Conclusion When making the decision to eliminate RT for low-risk vaginal ERMS patients, the risk of local recurrence should be considered and emphasized.

show abstract

Tumour expressions of hypoxic markers predict the response to neo-adjuvant chemotherapy in children with inoperable rhabdomyosarcoma

Cited by 14 publications

References 59 publications

GLUT-1 as a predictor of worse prognosis in pancreatic adenocarcinoma: immunohistochemistry study showing the correlation between expression and survival

GLUT-1 as a predictor of worse prognosis in pancreatic adenocarcinoma: immunohistochemistry study showing the correlation between expression and survival

<p>The Efficacy and Safety of Apatinib in Refractory/Relapse Advanced Pediatric Solid Tumor: A Retrospective Study</p>

Recurrence of low-risk vaginal embryonal rhabdomyosarcoma: A case report and literature review

Contact Info

Product

Resources

About